Fibronostics will be at the EASL2023 congress in Vienna!
Fibronostics will be guests at the EASL congress in Vienna, Austria to present ‘NAFLD: Diagnostics and non-invasive assessment’. Join Dr. Mona Munteanu, our Chief Scientific Officer, on 24 June
What is a Liver Blood Test?
Also known as a liver function test (LFT) or a liver panel test, a liver blood test is used to diagnose and monitor liver disease.
AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods.
AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods.
Fibronostics is proud to announce today that it has secured $6.5 million in funding. In addition – Sven Henrichwark, PhD, has been named the company’s new CEO.
NEW YORK and SINGAPORE, June 15, 2022 /PRNewswire/ — Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. In addition to
Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL).
Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver
